MedTrace Logo

A Phase IB Dose Escalation Study of Lipocurc in Patients With Cancer

NCT02138955 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-05-11

No results posted yet for this study

Summary

This is a single center in patient/outpatient, uncontrolled dose escalating study in cancer patients to evaluate the safety, tolerability and pharmacokinetic (PK) profiles of body surface area adjusted doses of liposomal curcumin administered intravenously as an 8 hour infusion once weekly for 8 weeks.

Conditions

  • Patients w/Advanced Cancer That Failed Std of Care Therapy

Interventions

DRUG

Liposomeal curcumin

Sponsors & Collaborators

  • SignPath Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Richard Greil, MD · Medicizinische Universitatsklinik Hematologie,Internistische Onkologie

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2017-11-30
Completion
2018-02-15

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02138955 on ClinicalTrials.gov